Phase 2 Randomized Double-Blind Placebo-Controlled 4-Period Single-Dose Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to the Efficacy of AD109 in Obstructive Sleep Apnea
Latest Information Update: 03 Feb 2023
At a glance
- Drugs AD 109 (Primary) ; Atomoxetine; Oxybutynin
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Apnimed
- 13 Oct 2021 According to an Apnimed media release, the company issued a press release today showcasing results from this study.
- 13 Oct 2021 Primary endpoint (Change in Hypoxic Burden (HB)) has been met, According to an Apnimed media release.
- 13 Oct 2021 Results published in an Apnimed Media Release.